When Rare Becomes Personal- My C9orf72 Journey

When I received my own positive C9orf72 carrier diagnosis, I began searching for answers everywhere I could find them. Eventually, that search led me down a path I never expected… into genetics, probability, and the strange comfort of statistics. I was trying to understand how something so devastating could also feel so invisible. It’s a complicated mix of fear, clarity, and strange empowerment that comes with it.

The United States population sits at roughly 342 million people. Around 33,000 Americans live with ALS. That translates to approximately one in every 10,374 people.

Imagine a small town of 10,000 residents. Statistically, one person in that entire town may be living with ALS at any given time. That rarity explains why many people have never encountered the disease directly. ALS is sparse enough to remain largely invisible to the public, yet catastrophic inside the homes it enters.

The cruelty of ALS is often described by the "Ice Bucket Challenge" co-founder Anthony Senerchia as a "glass coffin", the mind stays sharp while the body retreats. Because the disease progresses quickly and often confines individuals to their homes, the public rarely sees the full scope of its impact. If something is not visible, society struggles to grasp its urgency.

To visualize it another way, consider a sold-out professional sports arena holding 20,000 people. In that entire crowd, statistically, only two people would be living with ALS.

Compare that to breast cancer, where approximately one in eight women will be diagnosed during their lifetime. That visibility fuels awareness, funding, and recognizable advocacy symbols. ALS, by contrast, is rare enough that people often ask me if it even has a ribbon. That rarity creates isolation and contributes to limited research funding.

When a specific genetic mutation like C9orf72 is identified, the statistical lens shifts dramatically. The C9orf72 hexanucleotide repeat expansion is the most common known genetic cause of ALS, but it still represents an extremely small subset of cases.

At any given time in the United States, only about 1,800 to 2,500 people are living with C9orf72-related ALS. That translates to roughly one in 150,000 people nationwide.

Statistically, these are considered stochastic events, occurrences that arise without clear cause or fault. On paper, they are random. Living inside that fraction of a percentage, however, does not feel like math. For a person like me, or my mom, in that 1-unit of the ratio, the randomness doesn't feel like math; it feels like a target.

Yet knowledge also creates power. Identifying the C9orf72 mutation means we are not fighting an unnamed enemy. Researchers are actively developing gene-silencing therapies, biomarker tracking, and early-intervention treatments designed specifically to interrupt the toxic processes triggered by this mutation.

If I had been standing in this reality thirty years ago, the gene would still exist, but the research would not. Today, there are clinical trials, emerging therapies, and legitimate scientific momentum. That matters more than statistics ever could.